Second line therapy – current strategies and clinical management

Therapeutic options for the patient beyond 2nd line in mCRC

Optimal management of mCRC: From complexity to clarity

Biosimilars for Oncologists: what you need to know

Researching the Potential of Checkpoint Inhibitors in HCC Expect the unexpected

Putting the patient fiPutting the patient firstrst

Treatment Decisions for HR+, HER2– Advanced Breast Cancer

Clinical Evidence of Biosimilar Trastuzumab

Biosimilar in Oncology: Yesterday, Today and a Look Ahead: Welcome and Introduction

Clinical Efficacy of Atezolizumab in PD-L1 Subgroups Defined by SP142 and 22C3 IHC Assays in 2L+ NSCLC: Results From the Randomized OAK Study (ROCHE )/ Treating unresectable malignant pleural mesothelioma: current options and future outlook 2.

Clinical Efficacy of Atezolizumab in PD-L1 Subgroups Defined by SP142 and 22C3 IHC Assays in 2L+ NSCLC: Results From the Randomized OAK Study (ROCHE )/ Treating unresectable malignant pleural mesothelioma: current options and future outlook 1.

Can PARP inhibitors offer benefit for all patients with platinum-sensitive ovarian cancer?

ESMO guideline: supportive care, nutrition, cancer anorexia & cachexia syndrome

A look to the future: How are real-world research initiatives evolving?

The burden of CAT: acknowledging the risk

Optimal treatment sequencing in mCRC + Discussion